|
End-of-day quote
Palestine Exchange
2026-10-25
|
5-day change | 1st Jan Change | ||
| 3.400 USD | +0.59% |
|
-3.68% | +47.83% |
| 08-13 | Jerusalem Pharmaceuticals Co. Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
| 06-30 | Jerusalem Pharmaceuticals Announces Board Changes | CI |
| Market Cap | 122M 109M 101M 91.51M 171M 11.62B 174M 1.22B 481M 6.09B 459M 450M 19.19B | P/E 2024 |
13.7x | P/E 2025 | 8.13x |
|---|---|---|---|---|---|
| Enterprise Value | 112M 99.57M 91.99M 83.36M 156M 10.58B 159M 1.11B 438M 5.55B 418M 410M 17.48B | EV / Sales 2024 |
1.47x | EV / Sales 2025 | 1.47x |
| Free-Float |
34.87% | Yield 2024 |
2.09% | Yield 2025 | 3.26% |
| 1 day | +0.59% | ||
| 1 week | -3.68% | ||
| Current month | -3.68% | ||
| 1 month | -2.86% | ||
| 3 months | -4.76% | ||
| 6 months | -10.76% | ||
| Current year | +47.83% |
| 1 week | 3.38 | 3.45 | |
| 1 month | 3.36 | 3.6 | |
| Current year | 2.28 | 4 | |
| 1 year | 2 | 4 | |
| 3 years | 1.74 | 4 | |
| 5 years | 1.36 | 4 | |
| 10 years | 0.8 | 4 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 2013-06-30 | |
Mohammed Natour
DFI | Director of Finance/CFO | - | 2020-02-29 |
Lina Masrouji
CTO | Chief Tech/Sci/R&D Officer | - | 1988-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 91 | - | |
Nidal Kamal
BRD | Director/Board Member | - | - |
| Director/Board Member | - | - |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +0.59% | -3.68% | +70.00% | +82.31% | 122M | ||
| -2.54% | +1.31% | +54.27% | +117.14% | 1,135B | ||
| -1.42% | +3.23% | +38.56% | +74.05% | 635B | ||
| +0.16% | +0.08% | +25.29% | +96.64% | 505B | ||
| -0.31% | +3.09% | +44.14% | +64.55% | 378B | ||
| -1.34% | -0.47% | +66.04% | +40.18% | 358B | ||
| -0.68% | +2.65% | +22.98% | +49.15% | 295B | ||
| -1.20% | +3.04% | +2.33% | +21.60% | 266B | ||
| -1.79% | +1.57% | +50.56% | +61.40% | 237B | ||
| -0.73% | -0.10% | +29.02% | +99.06% | 193B | ||
| Average | -0.93% | +1.07% | +40.32% | +70.61% | 400.38B | |
| Weighted average by Cap. | -1.35% | +1.63% | +41.02% | +80.33% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 39.82M 35.56M 32.85M 29.77M 55.7M 3.78B 56.62M 395M 157M 1.98B 149M 146M 6.24B | 48.95M 43.71M 40.38M 36.59M 68.46M 4.65B 69.59M 486M 192M 2.43B 184M 180M 7.67B |
| Net income | 5.04M 4.5M 4.16M 3.77M 7.05M 478M 7.16M 50.01M 19.8M 251M 18.91M 18.5M 790M | 10.18M 9.09M 8.4M 7.61M 14.24M 967M 14.48M 101M 40.02M 506M 38.22M 37.4M 1.6B |
| Net Debt | -10.32M -9.22M -8.52M -7.72M -14.44M -980M -14.68M -102M -40.57M -513M -38.74M -37.91M -1.62B | -10.9M -9.73M -8.99M -8.15M -15.24M -1.03B -15.49M -108M -42.83M -542M -40.89M -40.02M -1.71B |
Employees
595
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-25 | US$3.400 | +0.59% | 9,200 |
| 26-10-22 | US$3.380 | -2.03% | 1,079 |
| 26-10-21 | US$3.450 | +2.68% | 20 |
- Stock Market
- Stocks
- JPH Stock
Select your edition
All financial news and data tailored to specific country editions
















